ResMed insiders dump $31M in shares as stock lingers near 52‑week low

ResMed (RMD) has experienced a stark imbalance between insider buying and selling over the last year, with a buy‑sell ratio of 0.00x. No insider purchase was reported, while six distinct insiders collectively sold $31,309,710. Such a one‑sided flow exceeds the $1 million threshold that typically flags material insider activity, and it occurs against a backdrop of a stock price that has slipped to the lower 11 percent of its 52‑week range.

The most aggressive seller is CEO Michael J. Farrell, who executed five separate sales of 8,009 shares each between June and October 2025, each transaction valued between $2.0 million and $2.3 million. In total, Farrell’s sales amount to $19,039,745, representing roughly 61 percent of all insider sell‑side value. The CFO followed with twelve sales totaling $6,578,218, while directors collectively disposed of $5,585,964 across twelve transactions. Even the broader C‑suite contributed $105,783 in sales, underscoring that the selling pressure is not confined to a single executive.

Monthly activity highlights a pronounced spike in August 2024, when insiders sold $16,147,359, the single largest monthly total in the period. Subsequent months also posted multi‑million sell‑offs, with November 2024 at $6,573,798 and a series of $3‑4 million sales from March through November 2025. The persistence of these disposals suggests more than routine diversification; the frequency and size of the CEO’s trades, in particular, resemble a cluster‑selling pattern that analysts often view as a cautionary signal.

From a market perspective, the stock’s current price of $209.40 reflects a 2.14 percent intraday gain but remains down 13.1 percent year‑to‑date. The RSI of 28 signals that the share price is technically oversold, a condition that sometimes precedes a rebound but can also indicate lingering weakness. ResMed’s recent corporate actions—including a $500 million acquisition in the restless‑leg space, a projected FY 2026 gross margin of 62‑63 percent, and a planned $175 million buyback program—have not translated into insider confidence, as evidenced by the continued outflow.

Investors should weigh the heavy insider selling against the company’s growth narrative. While the acquisition and margin expansion point to a bullish operational outlook, the absence of insider purchases and the magnitude of executive disposals raise questions about internal sentiment. In markets where insider behavior is a leading indicator, the current data set leans toward a defensive posture, especially given the stock’s proximity to its 52‑week low and the technical oversold reading.

Overall, the combination of zero insider buying, a $31 million sell‑off, and repeated high‑value sales by the CEO creates a risk profile that warrants close monitoring. Should the stock price begin to recover, any shift toward insider buying would be a critical counter‑signal. Until then, the prevailing insider activity suggests caution for investors weighing further exposure to ResMed.